"to be honest, that was what i had almost expected," she said.
.
.
-
.
- . .
- eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention. http://lm360.us/Eldringhoff-sister-of-Escatel-from-Rivarossa?Donklenei=127
.